- Home
- URGN vs RDCM Comparison
URGN vs RDCM Comparison
Compare URGN & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- RDCM
- Stock Information
- Founded
- URGN 2004
- RDCM 1985
- Country
- URGN United States
- RDCM Israel
- Employees
- URGN N/A
- RDCM N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- URGN Health Care
- RDCM Technology
- Exchange
- URGN Nasdaq
- RDCM Nasdaq
- Market Cap
- URGN 181.2M
- RDCM 210.9M
- IPO Year
- URGN 2017
- RDCM 1997
- Fundamental
- Price
- URGN $14.82
- RDCM $11.89
- Analyst Decision
- URGN Strong Buy
- RDCM Strong Buy
- Analyst Count
- URGN 9
- RDCM 2
- Target Price
- URGN $26.81
- RDCM $16.00
- AVG Volume (30 Days)
- URGN 5.9M
- RDCM 33.2K
- Earning Date
- URGN 08-12-2025
- RDCM 08-06-2025
- Dividend Yield
- URGN N/A
- RDCM N/A
- EPS Growth
- URGN N/A
- RDCM 111.69
- EPS
- URGN N/A
- RDCM 0.53
- Revenue
- URGN $91,871,000.00
- RDCM $63,477,000.00
- Revenue This Year
- URGN $36.65
- RDCM $18.09
- Revenue Next Year
- URGN $88.35
- RDCM $11.46
- P/E Ratio
- URGN N/A
- RDCM $24.10
- Revenue Growth
- URGN 8.98
- RDCM 18.21
- 52 Week Low
- URGN $3.42
- RDCM $9.08
- 52 Week High
- URGN $18.15
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- RDCM 39.94
- Support Level
- URGN $6.92
- RDCM $12.00
- Resistance Level
- URGN $15.22
- RDCM $13.02
- Average True Range (ATR)
- URGN 1.57
- RDCM 0.45
- MACD
- URGN 1.17
- RDCM -0.15
- Stochastic Oscillator
- URGN 96.49
- RDCM 5.56
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.